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The study of inherited predisposition to cancer is of clinical
relevance, because family members at high risk may be
helped by screening or by advice about prevention. It is also
of biological interest, because the families offer a means to
identify genes that may have important normal roles in the
control of growth and differentiation, and which when faulty
can predispose to malignancy.
The best known examples of inherited predisposition
account for only a small proportion of cancer incidence.
Early diagnosis and prophylactic surgery in the easily recog-
nised Mendelian inherited cancer syndromes (see below) will
save only perhaps 100-200 cancer deaths per year in the UK
(Peto & Easton, 1991). While this is very significant for those
families, it will clearly not have much impact on the total of
cancer deaths. Nevertheless, these syndromes are still import-
ant. Rare cases may be instructive in themselves; and
inherited cases may have lessons for cancers in general
because mutation of the same genes may be involved in the
development of the inherited and the more common non-
inherited forms of the same cancer.
These easily recognised inherited cancers are only the tip of
the iceberg (Peto, 1980; Ponder, 1990a). Inherited factors are
probably predominant in 10% or so of common cancers such
as breast or ovarian cancer; the problem is that predisposed
families are more difficult to recognise because these cancers
are common, and many 'families' will be due to chance.
Moreover, for these cancers there are no phenotypes which
are characteristic of the inherited form, such as the multiple
intestinal polyps which immediately identify a colonic cancer
as part of the inherited syndrome of familial adenomatous
polyposis (FAP). Finally, the largest part of inherited predis-
position may not give rise to obvious familial clustering of
cancer at all. To cause a 'cancer family', a gene must result in
cancer in most of the family members who inherit it. If the
cancer develops only in, say, one in ten gene carriers (that is,
the gene is incompletely penetrant), it is easy to see that
extensive family trees would be rare - and yet it can be
shown that a common gene of this type could result in most
of the incidence of a particular cancer being concentrated in
a minority of the population, with obvious implications for
public health (Peto, 1980).
The great advances in understanding inherited predisposi-
tion to cancer in the past decade have come from two
directions: molecular genetics and genetic epidemiology. The
predisposing genes for many of the inherited syndromes have
been mapped to small chromosomal regions by genetic lin-
kage - a method which requires no prior information as to
what the genes might be. Now each gene is gradually being
identified by more refined genetic mapping and its functions
investigated (Bishop, 1991). This development has been
entirely dependent upon progress in constructing the human
genome map in terms ofpolymorphic DNA markers: it is no
accident that the loci of six of the inherited cancer syndromes
were mapped in a single year (1987/88), as the resolution of
the map reached a critical point. In genetic epidemiology
probably the major advance has been the use of large truly
population-based studies to determine the extent of familial
association of common cancers and the risks to family
members (Claus et al., 1991; Peto & Easton, 1991). These
studies suggest that much of the observed familial clustering
of common cancers may, as in the inherited cancer syn-
dromes, be the result of rare dominantly-inherited genes of
strong effect. Accordingly, families have been collected and
analysed by genetic linkage; and the first positive results (in
pre-menopausal breast cancer) have just been reported (Hall
et al., 1990). In parallel, increasing awareness of familial risk
has resulted in the setting-up of familial cancer clinics to give
advice to individuals and families and to recommend screen-
ing or treatment where necessary.
Despite this progress, there is still a very long way to go.
Four genes associated with inherited cancer predisposition
have been cloned: those for retinoblastoma, for the
chromosome 1lip13 locus involved in Wilms tumour, for
neurofibromatosis type 1 (NF-1), and the p53 gene involved
in at least some families with Li-Fraumeni syndrome (in
which soft tissue sarcomas are associated with a number of
other cancers, notably young-onset breast cancer). To take
the NF-1 gene as an example, there is already a clue to its
function because it has regions of strong sequence homology
with the catalytic domain of different GTPase activating
(GAP) proteins, which appear to be components of the ras
signal transduction pathway (Martin et al., 1990). To move
from this information to a description of the disease in terms
of disordered cell biology, and from there to the wide diver-
sity of clinical and pathological effects seen in family
members (Ponder, 1990b) is likely to be a very long road
indeed. The first step is likely to be to understand the normal
function of the gene. For p53 and the retinoblastoma gene,
both of which were identified and cloned some years ago,
even this has not yet been fully accomplished.
For many inherited cancer syndromes screening has been
possible for some years, using the various 'marker'
phenotypes (for example, in FAP, intestinal polyps and
hypertrophy of the retinal pigmented epithelium). Treatment,
usually surgical, is available and is acceptable because the
risk of cancer is known to be high. Screening will be refined
by the development of linked DNA markers, because those
who can be shown not to have inherited the gene can be
removed from screening at an early age. In familial cancers
such as those of the breast or ovary, however, management is
not so straightforward. Awareness of risk is bringing more
women to seek advice: but with no phenotypic or DNA
markers currently available for the predisposing gene, and
with the mode of inheritance less clear-cut, risk estimates are
less precise. Screening methods exist and are widely recom-
mended, but there is very little evidence as to whether or not
they are effective. Because of the uncertainty about risk,
major prophylactic surgery, such as for breast cancer, will
often be unacceptable.
Mapping of the predisposing genes and development of
new DNA markers will resolve some of these difficulties, but
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will highlight others. It may be possible with DNA markers
to reassure some women who are shown not to be at risk,
but this cannot be done without identifying others who have
inherited the cancer gene. What of the young girl who is
found to have a gene which gives her (for example) on
average a 50% chance of developing breast cancer before age
60? Without an effective means of early diagnosis, this in-
formation will be hard to use for her benefit, and it may
bring anxiety and problems with insurance and employment.
In the long term, we can hope that finding the predisposing
genes and elucidating their effects will lead to acceptable
means of prevention or treatment for those at risk. More
immediately, however, we need to be clear what effect the
giving of genetic information has on doctors and families,
and we must address the difficult problem of evaluating the
benefits of family screening for these common cancers. These
are questions which, if they can be tackled at all, require a
concerted national approach. In the UK, the *Cancer Family
Study Group may provide the basis for such an approach,
and clinicians who would like more information are invited
to contact the group at the address below.
In the long term, the greatest opportunity to use
knowledge of inherited predisposition to reduce deaths from
cancer in the population as a whole may come not from
recognition of individuals at high risk in families, but
from what is coming to be called 'molecular epidemiology' -
the investigation of genetic polymorphisms which affect
individual susceptibility to exogenous or endogenous car-
cinogens, mostly without causing obvious familial clusters.
Finding the predisposed individuals and the responsible genes
will be difficult. Whereas the genes for familial cancers can be
mapped and identified empirically by genetic linkage, in the
absence of a cancer family that strategy is difficult to apply.
The alternative is to select candidate predisposing genes and
to test their involvement by case-control studies. There are
two problems. First, we do not know enough to choose the
best candidates. Second, the assays for the genes that have
been chosen so far have mostly relied on a metabolic
phenotype - for example, administration of a test substance
and measurement of the ratios of its metabolites in a subse-
quent urine sample. This is cumbersome, and except in pro-
spective studies, open to the criticism that the phenotype is
modified by the disease. Recently, however, DNA-based
assays for genetic variants in the genes of the cytochrome
P450 superfamily have been developed which can be used in
place of phenotypic assays (Gough et al., 1990). These
studies may be the prototype for those that will have the
greatest impact in the next decade.
*The Cancer Family Study Group is a national collaborative group
which includes scientists and clinicians from MRC (Edinburgh),
CRC (Cambridge, Manchester, Sutton), ICRF (London, Leeds),
many University Departments and Hospitals and participants from
several European centres. The group was set up some years ago to
coordinate studies of familial cancer in the UK. Members are cur-
rently evaluating the new findings in breast cancer in families from
the UK. For further information contact Miss Caroline Jenkinson,
ICRF, 3K Springfield House, Hyde Terrace, Leeds LS29LU.
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